Literature DB >> 9658099

Characterization of a live-attenuated retroviral vaccine demonstrates protection via immune mechanisms.

U Dittmer1, D M Brooks, K J Hasenkrug.   

Abstract

Live-attenuated retroviruses have been shown to be effective retroviral vaccines, but currently little is known regarding the mechanisms of protection. In the present studies, we used Friend virus as a model to analyze characteristics of a live-attenuated vaccine in protection against virus-induced disease. Highly susceptible mice were immunized with nonpathogenic Friend murine leukemia helper virus (F-MuLV), which replicates poorly in adult mice. Further attenuation of the vaccine virus was achieved by crossing the Fv-1 genetic resistance barrier. The minimum dose of vaccine virus required to protect 100% of the mice against challenge with pathogenic Friend virus complex was determined to be 10(3) focus-forming units of attenuated virus. Live vaccine virus was necessary for induction of immunity, since inactivated F-MuLV did not induce protection. To determine whether immune cells mediated protection, spleen cells from vaccinated donor mice were adoptively transferred into syngeneic recipients. The results indicated that immune mechanisms rather than viral interference mediated protection.

Entities:  

Mesh：

Substances：

Year:  1998        PMID： 9658099      PMCID： PMC109828     

Source DB:  PubMed          Journal:  J Virol        ISSN： 0022-538X            Impact factor:   5.103


  38 in total

1.  Protection by attenuated simian immunodeficiency virus in macaques against challenge with virus-infected cells.

Authors:  N Almond; K Kent; M Cranage; E Rud; B Clarke; E J Stott
Journal:  Lancet       Date:  1995-05-27       Impact factor: 79.321

2.  Susceptibility to two strains of Friend leukemia virus in mice.

Authors:  F Lilly
Journal:  Science       Date:  1967-01-27       Impact factor: 47.728

3.  Protective effects of a live attenuated SIV vaccine with a deletion in the nef gene.

Authors:  M D Daniel; F Kirchhoff; S C Czajak; P K Sehgal; R C Desrosiers
Journal:  Science       Date:  1992-12-18       Impact factor: 47.728

Review 4.  Host-range control of a retroviral disease: Friend erythroleukemia.

Authors:  M E Hoatlin; D Kabat
Journal:  Trends Microbiol       Date:  1995-02       Impact factor: 17.079

5.  Prevention of retrovirus-induced neurological disease by infection with a nonneuropathogenic retrovirus.

Authors:  M Czub; F J McAtee; S Czub; W P Lynch; J L Portis
Journal:  Virology       Date:  1995-01-10       Impact factor: 3.616

6.  High-titer immune responses elicited by recombinant vaccinia virus priming and particle boosting are ineffective in preventing virulent SIV infection.

Authors:  M D Daniel; G P Mazzara; M A Simon; P K Sehgal; T Kodama; D L Panicali; R C Desrosiers
Journal:  AIDS Res Hum Retroviruses       Date:  1994-07       Impact factor: 2.205

7.  Oncogenicity of Friend-virus-infected cells: determination of origin of spleen colonies by the H-2 antigens as genetic markers.

Authors:  F Wendling; P E Tambourin
Journal:  Int J Cancer       Date:  1978-10-15       Impact factor: 7.396

8.  Transgenic Fv-4 mice resistant to Friend virus.

Authors:  T I Limjoco; P Dickie; H Ikeda; J Silver
Journal:  J Virol       Date:  1993-07       Impact factor: 5.103

9.  Studies on the role of the host immune response in recovery from Friend virus leukemia. II. Cell-mediated immunity.

Authors:  B Chesebro; K Wehrly
Journal:  J Exp Med       Date:  1976-01-01       Impact factor: 14.307

10.  Host genetic control of recovery from Friend leukemia virus-induced splenomegaly: mapping of a gene within the major histocompatability complex.

Authors:  B Chesebro; K Wehrly; J Stimpfling
Journal:  J Exp Med       Date:  1974-12-01       Impact factor: 14.307
View more
  46 in total

1.  Kinetics of the development of protective immunity in mice vaccinated with a live attenuated retrovirus.

Authors:  U Dittmer; B Race; K J Hasenkrug
Journal:  J Virol       Date:  1999-10       Impact factor: 5.103

2.  Effective postexposure treatment of retrovirus-induced disease with immunostimulatory DNA containing CpG motifs.

Authors:  Anke R M Olbrich; Simone Schimmer; Klaus Heeg; Koen Schepers; Ton N M Schumacher; Ulf Dittmer
Journal:  J Virol       Date:  2002-11       Impact factor: 5.103

3.  Essential role for virus-neutralizing antibodies in sterilizing immunity against Friend retrovirus infection.

Authors:  Ronald J Messer; Ulf Dittmer; Karin E Peterson; Kim J Hasenkrug
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

4.  Reduction of retrovirus-induced immunosuppression by in vivo modulation of T cells during acute infection.

Authors:  Hong He; Ronald J Messer; Shimon Sakaguchi; Guojun Yang; Shelly J Robertson; Kim J Hasenkrug
Journal:  J Virol       Date:  2004-11       Impact factor: 5.103

5.  CD8+ T-cell dysfunction due to cytolytic granule deficiency in persistent Friend retrovirus infection.

Authors:  Gennadiy Zelinskyy; Shelly J Robertson; Simone Schimmer; Ronald J Messer; Kim J Hasenkrug; Ulf Dittmer
Journal:  J Virol       Date:  2005-08       Impact factor: 5.103

6.  Preinfection treatment of resistant mice with CpG oligodeoxynucleotides renders them susceptible to friend retrovirus-induced leukemia.

Authors:  Anke R M Olbrich; Simone Schimmer; Ulf Dittmer
Journal:  J Virol       Date:  2003-10       Impact factor: 5.103

7.  Comparative Evaluation of the Vaccine Efficacies of Three Adenovirus-Based Vector Types in the Friend Retrovirus Infection Model.

Authors:  Camilla Patrizia Hrycak; Sonja Windmann; Wibke Bayer
Journal:  J Virol       Date:  2019-10-15       Impact factor: 5.103

Review 8.  Pirate primates in uncharted waters: lymphocyte transfers in unrelated, MHC-matched macaques.

Authors:  Benjamin J Burwitz; Justin M Greene; David H O'Connor
Journal:  Curr HIV Res       Date:  2009-01       Impact factor: 1.581

9.  Differential Inhibitory Receptor Expression on T Cells Delineates Functional Capacities in Chronic Viral Infection.

Authors:  Jeffrey E Teigler; Gennadiy Zelinskyy; Michael A Eller; Diane L Bolton; Mary Marovich; Alexander D Gordon; Aljawharah Alrubayyi; Galit Alter; Merlin L Robb; Jeffrey N Martin; Steven G Deeks; Nelson L Michael; Ulf Dittmer; Hendrik Streeck
Journal:  J Virol       Date:  2017-11-14       Impact factor: 5.103

10.  CD4+ T cells develop antiretroviral cytotoxic activity in the absence of regulatory T cells and CD8+ T cells.

Authors:  Nora Manzke; Ilseyar Akhmetzyanova; Kim J Hasenkrug; Mirko Trilling; Gennadiy Zelinskyy; Ulf Dittmer
Journal:  J Virol       Date:  2013-03-27       Impact factor: 5.103
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.